CTOs on the Move


 
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.genmab.com
  • 902 Carnegie Center Suite 301
    Princeton, NJ USA 08540
  • Phone: 609.430.2481

Executives

Name Title Contact Details
Anthony Mancini
Executive Vice President and Chief Operating Officer Profile

Similar Companies

ThermoGenesis Holdings

ThermoGenesis Holdings, Inc. is an industry leader in the development and commercialization of automated cell processing technologies for the cell and gene therapy fields. We offer a full suite of solutions for automated clinical biobanking, point-of-care applications, and large scale cell processing and manufacturing for the emerging CAR-T immunotherapy market.

Lipomics Technologies

Lipomics Technologies is a West Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Targeted Genetics Corporation

Targeted Genetics Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Geneos Therapeutics

Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.

Portage Biotech

Portage is a unique entity in the world of biotechnology, catalyzing R&D to produce more quality clinical programs and maximize potential returns.